Table 1.
The P values are resultant from Pearson χ 2 test of association or Fishers Exact when an asterisk is included
| Variable | Calpain-9 expression in total patient cohort | Calpain-9 expression in patients that received endocrine therapy | ||||
|---|---|---|---|---|---|---|
| Low | High | P value | Low | High | P value | |
| Age | ||||||
| ≤40 years | 36 (4.6%) | 40 (5.1%) | 0.025 | 4 (1.4%) | 2 (0.7%) | 0.695* |
| >40 years | 429 (54.8%) | 278 (35.5%) | 160 (54.1%) | 130 (43.9%) | ||
| Size | ||||||
| ≤2 cm | 296 (38.0%) | 166 (21.3%) | 0.001 | 88 (29.7%) | 56 (18.9%) | 0.055 |
| >2 cm | 166 (21.3%) | 151 (19.4%) | 76 (25.7%) | 76 (25.7%) | ||
| Stage | ||||||
| 1 | 294 (37.7%) | 168 (21.6%) | 0.009 | 70 (23.6%) | 53 (17.9%) | |
| 2 | 128 (16.4%) | 115 (14.8%) | 73 (24.7%) | 64 (21.6%) | 0.784 | |
| 3 | 39 (5.0%) | 35 (4.5%) | 21 (7.1%) | 15 (5.1%) | ||
| Grade | ||||||
| 1 | 87 (11.2%) | 48 (6.2%) | 0.255 | 8 (2.7%) | 8 (2.7%) | 0.498 |
| 2 | 155 (19.9%) | 101 (13.0%) | 53 (17.9%) | 50 (16.9%) | ||
| 3 | 220 (28.2%) | 168 (21.6%) | 103 (34.8%) | 74 (25.0%) | ||
| Nottingham prognostic index | ||||||
| <3.4 | 158 (20.3%) | 71 (9.1%) | 0.002 | 7 (2.4%) | 7 (2.4%) | 0.909 |
| 3.4-5.4 | 219 (28.2) | 176 (22.7%) | 117 (39.5%) | 94 (31.8%) | ||
| >5.4 | 83 (10.7%) | 70 (9.0%) | 40 (13.5%) | 31 (10.5%) | ||
| Basal status | ||||||
| Non-basal | 351 (46.9%) | 240 (46.9%) | 0.582 | 138 (48.6%) | 104 (36.6%) | 0.257 |
| Basal | 90 (12.0%) | 68 (9.1%) | 20 (7.0%) | 22 (7.7%) | ||
| ER status | ||||||
| Negative | 105 (13.8%) | 97 (12.8%) | 0.014 | 26 (9.0%) | 29 (10.0%) | 0.180 |
| Positive | 345 (45.5%) | 212 (27.9%) | 134 (46.4%) | 100 (34.6%) | ||
| PgR status | ||||||
| Negative | 183 (24.3%) | 138 (18.3%) | 0.246 | 64 (22.6%) | 51 (18.0%) | 0.257 |
| Positive | 265 (35.1%) | 168 (22.3%) | 96 (33.9%) | 72 (25.4%) | ||
| HER2 status | ||||||
| Negative | 394 (51.5%) | 264 (34.5%) | 0.099 | 131 (45.5%) | 111 (38.5%) | 0.765 |
| Positive | 55 (7.2%) | 52 (6.8%) | 26 (9.0%) | 20 (6.9%) | ||
| Lymphovascular invasion | ||||||
| Negative | 255 (36.9%) | 168 (26.1%) | 0.490 | 82 (32.2%) | 76 (29.8%) | 0.164 |
| Positive | 127 (19.7%) | 94 (14.6%) | 59 (23.1%) | 38 (14.9%) | ||
Significant P values are indicated by bold. The immunohistochemistry cohort was comprised of 783 patients; however, scores were not available for every patient for each marker. The number of observations for each marker is shown for each clinicopathological variables and percentage in parentheses. NPI is Nottingham prognostic index, ER is oestrogen receptor, PgR is progesterone receptor.